# Day 100 Absolute Monocyte/Lymphocyte Prognostic Score and Survival Post Autologous Peripheral Blood Hematopoietic Stem Cell Transplantation in Diffuse Large B-Cell Lymphoma

## TL;DR

This study identifies a new biomarker score based on blood cell counts at day 100 after a stem cell transplant to predict survival in diffuse large B-cell lymphoma patients.

## Contribution

The study introduces the AMLPS-100 score as a novel prognostic tool for DLBCL patients post-transplant.

## Key findings

- High AMC-100 and low ALC-100 are independently associated with worse survival outcomes.
- AMLPS-100 risk groups show significant differences in 5-year OS and PFS rates.
- AMLPS-100 is a simple and effective biomarker for stratifying clinical outcomes.

## Abstract

Day 100 prognostic factors post-autologous peripheral blood hematopoietic stem cell transplantation (APBHSCT) to predict clinical outcomes in diffuse large B-cell lymphoma (DLBCL) patients have not been studied. Thus, we retrospectively examined if day 100 absolute monocyte/lymphocyte prognostic score (AMLPS-100) affects clinical outcomes by landmark analysis from day 100 post-APBHSCT in DLBCL. Only DLBCL patients in complete remission at day 100 post-APBHSCT were evaluated. From 2000 to 2007, 134 consecutive DLBCL patients are qualified for the study. Patients with a day 100 absolute monocyte count (AMC-100) ≥ 630 cells/μL and day 100 absolute lymphocyte count (ALC-100) ≤ 1000 cells/μL experienced inferior overall survival (OS) and progression free survival (PFS). On multivariate analysis, the AMC-100 and ALC-100 remained independent predictors of OS and PFS. Combining both values into the AMLPS-100, the 5-year OS rates for low, intermediate, and high AMLPS-100 risk groups were 94% (95% CI, 83.0% – 98.1%), 70% (95% CI, 58.6% – 80.1%), and 13% (95% CI, 3.4% – 40.5%), respectively; and the 5-year PFS rates were 87% (95% CI, 74.0% – 94.1%), 68% (95% CI, 56.0% – 77.8%), and 13% (95% CI, 3.4% – 40.5%), respectively. The AMLPS-100 is a simple biomarker score that can stratify clinical outcomes from day 100 post-APBHSCT in DLBCL patients.